EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis

Eva Cabrera César, Javier López Garcia, Miguel Benitez Cano Gamonoso, Cecilia López Ramirez, Beatriz Jiménez Rodriguez, Ana Dolores Romero Ortiz, Zulema Palacios Hidalgo, David Fole Vázquez, Patricia Guerrero Zamora, Natalia Mena Vázquez, Antonio Hidalgo Molina, Inés De La Cruz Morón und 5 weitere

Medicina Clínica · 2025

DOI: 10.1016/j.medcli.2025.107169 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2025. Verfasst von Eva Cabrera César und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: evacabreracesar@gmail.com. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Indoles, Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with non-idiopathic interstitial lung diseases can develop progressive pulmonary fibrosis (PPF-ILD). The study objectives were to define the profile of patients with PPF-ILD treated with nintedanib and to assess the effectiveness and safety of this drug in a real-world setting. METHODS: This was a multicenter, prospective, observational study of adult patients with PPF-ILD that initiated treatment with nintedanib in ten Andalusian hospitals (Spain). Demographic data, smoking habit, underlying disease, and diagnosis criteria were recorded. Pulmonary function test results, the dyspnea scale score, and the number of hospitalizations related to PPF-ILD were evaluated at baseline and after 6 and 12 months. Adverse events were recorded. RESULTS: Between July 2021 and March 2023, a total of 145 patients entered the study and were followed up until March 2024; 55% were men and the mean age was 66.6±11.5 years. PPF-ILD was diagnosed based on clinical, radiological and pulmonary function test findings in 97 patients (66.9%). The mean±SD duration of nintedanib therapy was 13.3±10.1 months. Dyspnea improved, although the difference was not statistically significant. FVC % and DLCO % stabilized. The number of hospitalizations related to PPF-ILD was reduced (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIndolesPulmonary FibrosisProtein Kinase InhibitorsHumansMaleFemaleAgedProspective StudiesMiddle AgedDisease ProgressionHospitalizationTreatment OutcomeSpain

Stichwörter der Autor:innen

Enfermedades pulmonares intersticiales no idiopáticasEstudio en vida realFibrosis pulmonar progresivaNintedanibNon-idiopathic interstitial lung diseasesProgressive pulmonary fibrosisReal-world study

Substanzen

nintedanibIndolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: evacabreracesar@gmail.com.
  • Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Hospital Universitario Virgen de Valme, Sevilla, Spain.
  • Hospital Universitario Torrecárdenas, Almería, Spain.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Cabrera César, E., López Garcia, J., Cano Gamonoso, M. B., López Ramirez, C., Jiménez Rodriguez, B., Romero Ortiz, A. D., Palacios Hidalgo, Z., Fole Vázquez, D., Guerrero Zamora, P., Mena Vázquez, N., Hidalgo Molina, A., De La Cruz Morón, I., Espildora Hernández, F., Cruz Medina, A., Lacarcel Bautista, C., Vegas Viñas, A., & Velasco Garrido, J. L. (2025). Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis. Medicina Clínica. https://doi.org/10.1016/j.medcli.2025.107169

Vancouver

Cabrera César E, López Garcia J, Cano Gamonoso MB, López Ramirez C, Jiménez Rodriguez B, Romero Ortiz AD, et al. Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis. Medicina Clínica. 2025. doi:10.1016/j.medcli.2025.107169

BibTeX
@article{CabreraCsar2025,
  author = {Cabrera César, Eva and López Garcia, Javier and Cano Gamonoso, Miguel Benitez and López Ramirez, Cecilia and Jiménez Rodriguez, Beatriz and Romero Ortiz, Ana Dolores and Palacios Hidalgo, Zulema and Fole Vázquez, David and Guerrero Zamora, Patricia and Mena Vázquez, Natalia and Hidalgo Molina, Antonio and De La Cruz Morón, Inés and Espildora Hernández, Francisco and Cruz Medina, Antonio and Lacarcel Bautista, Celia and Vegas Viñas, Adriana and Velasco Garrido, José Luis},
  title = {Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis},
  journal = {Medicina Clínica},
  year = {2025},
  doi = {10.1016/j.medcli.2025.107169}
}
Kostenlos starten →